Hemoperfusion during Coronary Artery Bypass Grafting Promotes Lipid-Lowering in Familial Hypercholesterolemia

Kang Zhou1, Jianfeng Zhang1, Chang Wang2, Daoquan Peng2 and Yuan Zhao1*

1Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, China
2Department of Cardiology, The Second Xiangya Hospital of Central South University, China

^*Correspondance to: Yuan Zhao 

 PDF  Full Text Case Report | Open Access

Abstract:

Patients with Familial Hypercholesterolemia (FH) presented with early-onset Coronary Heart
Disease (CAD) usually require Coronary Artery Transplantation (CABG) treatment. However,
the effect of lipid-lowering therapy plays a critical role in long-term survival. In this case, a young
woman was clinically diagnosed as homozygous FH and received CABG under Cardiopulmonary
Bypass (CPB). During CPB, we used hemoperfusion to lower blood lipids and found that its effect
was much better than other lipid-lowering therapies. This case enables us to further realize the
importance of hemoperfusion for lipid-lowering therapy in patients with homozygous FH.

Keywords:

Familial hypercholesterolemia; Xanthomas; Coronary artery disease; Hemoperfusion

Cite the Article:

Zhou K, Zhang J, Wang C, Peng D, Zhao Y. Hemoperfusion during Coronary Artery Bypass Grafting Promotes Lipid-Lowering in Familial Hypercholesterolemia. World J Surg Surgical Res. 2021; 4: 1329..